By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CSL Behring 

1020 First Avenue
P.O. Box 61501
King of Prussia  Pennsylvania  19406-0901  U.S.A.
Phone: 610-878-4000 Fax: 610-878-4009



Company News
CSL Behring Release: FDA Approves HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), First And Only Subcutaneous Preventive Treatment For Hereditary Angioedema 6/26/2017 6:31:40 AM
CSL Behring Release: Jeffrey Modell Foundation To Open The First North African Network For Primary Immunodeficiencies 3/31/2017 9:39:07 AM
CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients 3/30/2017 7:32:36 AM
The New England Journal of Medicine Publishes Pivotal Phase III Data For CSL Behring's Subcutaneous C1-Esterase Inhibitor In HAE Patients 3/23/2017 6:16:33 AM
CSL Behring Release: Largest Ever CIDP Clinical Study Completed 3/1/2017 8:13:56 AM
20/20 GeneSystems Announces HSR Clearance For Collaboration And License Agreement With Momenta (MNTA) 2/17/2017 8:53:59 AM
FDA Accepts CSL Behring's Biologics License Application Supplement For Using Privigen To Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), A Rare Neurological Condition 2/14/2017 7:53:35 AM
CSL Behring Release: AFSTYLA, For Haemophilia A, Receives European Commission Approval 1/9/2017 8:38:22 AM
Health Canada Approves CSL Behring's AFSTYLA For The Treatment Of Hemophilia A 12/15/2016 7:16:22 AM
CSL Behring Presents New Phase III Analysis Of IDELVION For Hemophilia B At The 2016 American Society of Hematology Annual Meeting 12/5/2016 6:34:20 AM